The model of this well-financed two-year-old start-up harks back to the mid-to-late 1990s when technology promised to provide industrial-age solutions to the handcraft of drug R&D. Its investor list likewise recalls earlier years: one of its key venture funds, Kleiner Perkins, once at the forefront of biotech investing has largely remained on the sidelines since the mid-1990s. Even its vocabulary echoes older ambitions--FivePrime aims to mine the pharmanome, just as companies in the late 1990s aimed to mine the proteome, peptidome, metabolome, cytome, glycome and cellome.
951 Gateway Boulevard
South San Francisco, CA 94080
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
